VBC-Genomics Bioscience Research GmbH (LLC).

Abstract:

:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the development of diagnostic assays based on microarrays. A technical platform for amplification and analysis of DNA has been established and validated in clinical studies. In addition, the company has developed the world's first protein microarray that is certified as an in vitro diagnostic device. This microarray contains allergen components and provides a powerful assay for the profiling of numerous allergy disease-related antigens. The company also markets technological skills and array development expertise to academics and industry.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Schmidt WM

doi

10.1517/14622416.5.4.439

keywords:

subject

Has Abstract

pub_date

2004-06-01 00:00:00

pages

439-42

issue

4

eissn

1462-2416

issn

1744-8042

pii

PGS050412

journal_volume

5

pub_type

杂志文章
  • Gene expression correlates of unexplained fatigue.

    abstract::Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.7.3.395

    authors: Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

    更新日期:2006-04-01 00:00:00

  • The application of CD antigen proteomics to pharmacogenomics.

    abstract::The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.5.759

    authors: Woolfson A,Ellmark P,Chrisp JS,A Scott M,Christopherson RI

    更新日期:2006-07-01 00:00:00

  • Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.

    abstract:BACKGROUND:Clobazam-induced adverse reactions have been reported in cases with CYP2C19 defective allele(s). However, the relevance of the CYP2C19 genotypes to clobazam therapy remains to be clarified. METHODS:The association between CYP2C19 genotypes and the antiepileptic and adverse effects of clobazam was retrospect...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.5.527

    authors: Seo T,Nagata R,Ishitsu T,Murata T,Takaishi C,Hori M,Nakagawa K

    更新日期:2008-05-01 00:00:00

  • Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.

    abstract::The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.46

    authors: Sipeky C,Csongei V,Jaromi L,Safrany E,Polgar N,Lakner L,Szabo M,Takacs I,Melegh B

    更新日期:2009-06-01 00:00:00

  • Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

    abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.3.217

    authors: Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

    更新日期:2007-03-01 00:00:00

  • Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD.

    abstract::Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0120

    authors: Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

    更新日期:2021-01-01 00:00:00

  • DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.

    abstract::Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0058

    authors: Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

    更新日期:2019-08-01 00:00:00

  • Pharmacogenetics of chemotherapy efficacy in breast cancer.

    abstract::Large differences are observed in chemotherapy response between breast cancer patients, with a substantial part of this variability being explained by genetic factors. Polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets influence the pharmacokinetics and pharmacodynamics of th...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.44

    authors: González-Neira A

    更新日期:2012-04-01 00:00:00

  • Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.

    abstract::Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.45

    authors: Lee AK,Bishop JR

    更新日期:2011-07-01 00:00:00

  • Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART.

    abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.9.1347

    authors: Nakajima T,Kimura A

    更新日期:2008-09-01 00:00:00

  • The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.

    abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0182

    authors: Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

    更新日期:2019-05-01 00:00:00

  • Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

    abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.6.7.731

    authors: Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

    更新日期:2005-10-01 00:00:00

  • Parkinson's disease pharmacogenomics: new findings and perspectives.

    abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.93

    authors: Schumacher-Schuh AF,Rieder CR,Hutz MH

    更新日期:2014-06-01 00:00:00

  • Meta-analysis in genome-wide association studies.

    abstract::The advent of genome-wide association studies has allowed considerable progress in the identification and robust replication of common gene variants that confer susceptibility to common diseases and other phenotypes of interest. These genetic effect sizes are almost invariably moderate to small in magnitude and single...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.10.2.191

    authors: Zeggini E,Ioannidis JP

    更新日期:2009-02-01 00:00:00

  • Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.

    abstract:AIMS:To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS:This was a multicenter prospective study. One hundred and forty four pa...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2217/pgs.12.53

    authors: Tian J,Qin X,Fang K,Chen Q,Hou J,Li J,Yu W,Chen D,Hu Y,Li X

    更新日期:2012-05-01 00:00:00

  • Functional characterization of CYP2D7 gene variants.

    abstract::The ultrarapid CYP2D6 metabolizer (UM) phenotype is caused by CYP2D6 gene duplications in some, but not all, UM individuals. CYP2D6 and the adjacent pseudogene CYP2D7 are highly homologous; however, CYP2D7 harbors a premature stop codon, which is absent in carriers of the rare CYP2D7 variant rs530303678. We addressed ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0065

    authors: Jukic MM,Lauschke VM,Saito T,Hiratsuka M,Ingelman-Sundberg M

    更新日期:2018-08-01 00:00:00

  • Adducin polymorphisms and the treatment of hypertension.

    abstract::Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in h...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.5.465

    authors: Manunta P,Citterio L,Lanzani C,Ferrandi M

    更新日期:2007-05-01 00:00:00

  • Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

    abstract::In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.44

    authors: Awada Z,Zgheib NK

    更新日期:2014-04-01 00:00:00

  • The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.

    abstract::High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.5.525

    authors: Almon RR,DuBois DC,Piel WH,Jusko WJ

    更新日期:2004-07-01 00:00:00

  • Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.

    abstract::Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.62

    authors: Frueh FW

    更新日期:2009-07-01 00:00:00

  • Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.

    abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.14.52

    authors: Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

    更新日期:2014-05-01 00:00:00

  • Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.

    abstract::Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.223

    authors: Schweighofer N,Lerchbaum E,Trummer O,Schwetz V,Pieber T,Obermayer-Pietsch B

    更新日期:2014-02-01 00:00:00

  • International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.

    abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.58

    authors: Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

    更新日期:2015-01-01 00:00:00

  • Genetic variants associated with warfarin dosage in Kuwaiti population.

    abstract::Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0020

    authors: John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

    更新日期:2017-06-01 00:00:00

  • Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics.

    abstract::Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.12.1809

    authors: Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

    更新日期:2008-12-01 00:00:00

  • The genetics of fibromyalgia syndrome.

    abstract::Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.1.67

    authors: Buskila D,Sarzi-Puttini P,Ablin JN

    更新日期:2007-01-01 00:00:00

  • Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.

    abstract::Mother-to-child-transmission rates of HIV in the absence of any intervention range between 20 and 45%. However, the provision of antiretroviral drugs (ARVs) during pregnancy, delivery and breastfeeding can reduce HIV transmission to less than 2%. Physiological changes during pregnancy can influence ARV disposition. As...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.138

    authors: Olagunju A,Owen A,Cressey TR

    更新日期:2012-10-01 00:00:00

  • Genetic determinants of warfarin dosing in the Han-Chinese population.

    abstract:UNLABELLED:Warfarin, a widely prescribed oral anticoagulant, is used for the prevention of thromboembolism. Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements. However, it is likely that other genes could also affect warfarin dose. AIMS:In this study, we aimed to identi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.106

    authors: Lee MT,Chen CH,Chou CH,Lu LS,Chuang HP,Chen YT,Saleem AN,Wen MS,Chen JJ,Wu JY,Chen YT

    更新日期:2009-12-01 00:00:00

  • DNA methylation biomarkers of cancer: moving toward clinical application.

    abstract::While different markers for cancer diagnosis have been known for at least a decade, the systematic search for biomarkers emerged only several years ago. In this article, I will concentrate on DNA methylation as a dynamic and robust platform for the development of cancer-specific biomarkers. Simultaneous analysis of a ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.5.6.699

    authors: Levenson VV

    更新日期:2004-09-01 00:00:00

  • Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.

    abstract::Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.3.297.22687

    authors: Ameen M

    更新日期:2003-05-01 00:00:00